The combination of silymarin and pegylated interferon alpha2b attenuates the progression of liver fibrosis in prior nonresponders and relapsers with chronic hepatitis C infection…

Background: The aim of this investigation was to study the effect of maintenance pegylated interferon with and without Silymarin on fibrosis progression in patients with chronic Hepatitis C virus infection, who failed prior therapy. Material and Methods: In a prospective and randomized multi-center trial patients were treated for 24 months with a combination of pegylated interferon a2b (100µg/week or 50µg/every other week) and oral silymarin (3×280mg per day) or placebo, followed by an additional 3 months post-treatment survey. Viral load, serological parameters, histological scoring and surrogate fibrosis marke…